onc Videos

Videos

Treating Patients With Relapsed/Refractory Mantle Cell Lymphoma: Part 3

11/13/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...

In this expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD on the best options for treating patients with relapsed/refractory mantle cell lymphoma.

In this expert roundtable...

11/13/2023

Oncology

Conference Coverage

Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer

11/10/2023

Featuring Oleg Gluz, MD

Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.

Oleg Gluz, MD, Evangelical...

11/10/2023

Oncology

SPONSORED VIDEO

HER2-Low Breast Cancer Roundtable: Decoding HER2-Low Expression in Metastatic Breast Cancer

11/10/2023

This roundtable discussion is sponsored by Daiichi Sankyo. Dr Adam Brufsky: So, hello, my name is Dr Adam Brufsky. I'm a professor of medicine at the University of Pittsburgh, and welcome today to our Oncology Learning Network Roundtable...

This roundtable discussion is...

11/10/2023

Oncology

Philip Kuo, MD, PhD, University of Arizona Cancer Center

Videos

Association Between Baseline PSMA Expression and Response to 177Lu-PSMA-617 Among Patients with Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Featuring Philip Kuo, MD, PhD

Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...

Philip Kuo, MD, PhD, shares...

11/10/2023

Oncology

Videos

Approaches to Frontline Therapy for Patients With Mantle Cell Lymphoma: Part 2

11/09/2023

Featuring Kami Maddocks, MD, Jia Ruan, MD, PhD, and Krish Patel, MD

Featuring Kami Maddocks, MD, Jia Ruan...

In the second part of an expert roundtable series, Kami Maddocks, MD, leads a discussion with Jia Ruan, MD, PhD, and Krish Patel, MD on goals and choice of frontline therapy for patients with mantle cell lymphoma.

In the second part of an expert...

11/09/2023

Oncology

Conference Coverage

Tisotumab Vedotin Improves Survival, Response Among Patients With Recurrent or Metastatic Cervical Cancer

11/08/2023

Featuring Ignace Vergote, MD, PhD

Featuring Ignace Vergote, MD, PhD ...

Ignace Vergote, MD, PhD, discusses results from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial.

Ignace Vergote, MD, PhD,...

11/08/2023

Oncology

Berend van der Wilk, MD, Erasmus University Medical Center

Videos

Active Surveillance After Neoadjuvant Chemoradiation for Select Patients With Esophageal Cancer

11/07/2023

Featuring Berend van der Wilk, MD

Featuring Berend van der Wilk, MD ...

Berend van der Wilk, MD, shares results from a phase 3 trial comparing active surveillance with surgery following neoadjuvant chemoradiotherapy for patients with esophageal cancer.

Berend van der Wilk, MD, shares...

11/07/2023

Oncology

Elias Jabbour, MD, MD Anderson Cancer Center

Videos

Exploring Chemotherapy-Free Treatment for Patients With Philadelphia-Positive ALL

11/07/2023

Featuring Elias Jabbour, MD

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.

At the 2023 Lymphoma, Leukemia &...

11/07/2023

Lymphoma, Leukemia & Myeloma Network

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology